Skip to main content
Applied Companion Skin Health Companion

Applied Companion

Skin Health Companion

A structured companion for organizing skin-care routines, monitoring visible and sensory changes, tracking triggers and treatment response, preparing photographs and questions, and recognizing infection warning signs.

Format digital
Access $39.00
Item ID acd044

Educational support only. This resource complements, not replaces, provider instructions, facility policy, or medical advice.

Item Details

About this resource

Start here

The essentials before you go deeper.

Skin Health Companion
Why This Companion Matters

Managing skin health can become complicated when symptoms, instructions, appointments, and daily responsibilities are spread across different people and places. This companion is designed for people monitoring recurrent, changing, or functionally disruptive skin concerns between visits. It creates one organized location for the observations, questions, and provider-directed information that are most useful between visits. The goal is not to make the reader responsible for diagnosing or treating a health problem. The goal is to make the lived experience easier to describe, the plan easier to follow, and conversations with qualified professionals more productive.

What This Companion Helps Organize

The companion brings together location, appearance, photographs, itch, pain, drainage, swelling, exposures, products, treatment response, infection concerns, sleep disruption, clothing tolerance, and questions about change over time. Guided check-ins help the reader record what happened, when it happened, what was being done at the time, how long the change lasted, and how it affected daily function. This creates a more useful picture than isolated memories or a single symptom rating. It also gives the reader a dependable place to retain instructions, write down questions before appointments, and note the next steps established by the care team.

Daily Life and Participation

Health concerns matter because of what they change in everyday life. This companion connects observations and care-team guidance with bathing, dressing, sleep, work, exercise, intimacy, social activity, and confidence participating outside the home. The reader can identify activities that have become harder, patterns that improve or worsen participation, supports that have been helpful, and priorities to discuss at the next visit. Short, structured prompts are used so the resource can remain practical even on difficult or low-energy days.

Working With the Care Team

The companion supports communication with primary-care, dermatology, allergy, wound-care, pharmacy, and rehabilitation professionals. It can be brought to appointments to clarify recent changes, confirm instructions, compare priorities, and reduce the chance that important questions will be forgotten. Any goals, precautions, action thresholds, medications, exercises, equipment recommendations, dietary directions, or progression decisions recorded in the book should come from the appropriate qualified professional. When instructions differ, the reader should pause and ask the responsible clinician to clarify the current plan.

Patterns, Check-Ins, and Preparation

Repeated check-ins make it easier to notice whether a concern is stable, improving, worsening, or changing in a new way. The reader can record dates, circumstances, functional effects, and questions without being expected to keep a lengthy daily journal. Appointment-preparation pages help translate those observations into concise information: what has changed, what matters most now, what has already been tried, and what needs professional review.

Safety Awareness

This resource includes space to retain individualized safety and escalation instructions. Prompt professional or emergency evaluation may be needed for rapidly spreading redness, severe pain, fever, facial or airway swelling, extensive blistering, signs of serious infection, or a rapidly changing lesion requiring prompt evaluation. This list is not exhaustive and does not replace the emergency directions given by a licensed professional. If symptoms are urgent, severe, rapidly worsening, or outside the expected pattern, the reader should use emergency services or contact the appropriate care team as directed.

Who May Find It Useful

This companion may be useful for the person experiencing the concern, family members or caregivers who assist with organization, and professionals who want a clearer view of changes between visits. It is intentionally flexible because individual needs, diagnoses, environments, and care plans differ. Sections can be used according to relevance while the clinical plan remains under professional direction.

Educational Scope

The Skin Health Companion supports education, organization, preparation, reflection, and communication. It does not diagnose, prescribe, establish a treatment protocol, interpret emergency symptoms, or replace individualized medical, behavioral-health, rehabilitation, nutrition, pharmacy, or emergency guidance. CarePlanCompass™ publications complement—not replace—clinical care.

skin health companion visible sensory and functional changes routine products itch pain photographs exposure patterns treatment response infection concerns provider questions CarePlanCompass digital companion

Next Step Hub

Your next best move starts here.

Choose the matched bundle, continue with this resource, review connected tools, or check the evidence behind the guidance.

Best matched next step

Skin Health Bundle

Built for users who want this Companion plus the most useful connected supports in one organized pathway.

Allergy Management Companion Condition Overview & What to Expect Skin Symptom & Change Tracker Provider Visit & Photo Log
This resource

Continue with this item

Use this path when this resource is the book, guide, or support tool you came for.

Get Access

Connected Tools

Related pathway tools

8 items
Applied Companion Allergy Management Companion
View
Guidance Resource Condition Overview & What to Expect
View
Guidance Resource Skin Symptom & Change Tracker
View
Guidance Resource Provider Visit & Photo Log
View
Guidance Resource Infection & Wound Red Flags
View
Guidance Resource Flare-Up Protocol
View
View all related tools
Guidance Resource Skin-Care Routine Planner
View
Guidance Resource Skin Trigger Tracker
View

Clinical Confidence

Evidence behind this resource

20 sources
Evidence-informed

Guidance is connected to the CarePlanRx™ reference database.

AMA-style references

Sources are formatted for clinical review and transparency.

Methodology available

Users can review how references support the resource framework.

View Clinical Evidence & Methodology

View clinical references 20 sources
  1. Chu AWL, Wen A, Guyatt GH, Rao M, Bakaa L, Zhao IX et al. Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. BMJ (Clinical research ed.). 2026;394:e100163. doi:10.1136/bmj-2026-100163 Source
  2. Singleton H, Hodder A, Almilaji O, Ersser SJ, Heaslip V, O'Meara S et al. Educational and psychological interventions for managing atopic dermatitis (eczema). The Cochrane database of systematic reviews. 2024;8(8):CD014932. doi:10.1002/14651858.CD014932.pub2 Source
  3. Chu AWL, Wong MM, Rayner DG, Guyatt GH, Díaz Martinez JP, Ceccacci R et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. 2023;152(6):1470-1492. doi:10.1016/j.jaci.2023.08.029 Source
  4. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R et al. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The Journal of allergy and clinical immunology. 2023;151(1):147-158. doi:10.1016/j.jaci.2022.09.020 Source
  5. Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. 2023;152(6):1493-1519. doi:10.1016/j.jaci.2023.08.030 Source
  6. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA dermatology. 2022;158(5):523-532. doi:10.1001/jamadermatol.2022.0455 Source
  7. Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J et al. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. The journal of allergy and clinical immunology. In practice. 2022;10(10):2657-2666.e8. doi:10.1016/j.jaip.2022.06.044 Source
  8. Roongpisuthipong W, Klangjareonchai T, Kurathong S, Roongpisuthipong A. Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial. The Journal of dermatological treatment. 2026;37(1):2604448. doi:10.1080/09546634.2025.2604448 Source
  9. Wang S, Li F. Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: a post-hoc analysis of a phase III trial. Naunyn-Schmiedeberg's archives of pharmacology. 2026;399(2):2417-2425. doi:10.1007/s00210-025-04490-4 Source
  10. Heidari Z, Gharibi G, Alaeen H, Ghadrdan E, Shahrestanaki E, Sadeghi-Ghadi Z et al. Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial. Journal of pineal research. 2026;78(2):e70130. doi:10.1111/jpi.70130 Source
  11. Yosipovitch G, Lio PA, Rosmarin D, Legat FJ, Serra-Baldrich E, Carrascosa JM et al. Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. Dermatology (Basel, Switzerland). 2025;241(4):325-335. doi:10.1159/000547142 Source
  12. Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D et al. Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials. Advances in therapy. 2025;42(4):1800-1810. doi:10.1007/s12325-025-03124-8 Source
  13. Zhu C, Feng B, Pan J, Ma J, Hu B, Liu L. Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial. The Journal of dermatological treatment. 2025;36(1):2558995. doi:10.1080/09546634.2025.2558995 Source
  14. Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet (London, England). 2024;404(10451):445-460. doi:10.1016/S0140-6736(24)01203-0 Source
  15. Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). The British journal of dermatology. 2024;192(1):36-45. doi:10.1093/bjd/ljae404 Source
  16. Kurt T, Vossen D, Schumacher F, Strunk J, Fedkov D, Peine C et al. Effect of Lifestyle Counselling via a Mobile Application on Disease Activity Control in Inflammatory Arthritis: A Single-Blinded, Randomized Controlled Study. Nutrients. 2024;16(10). doi:10.3390/nu16101488 Source
  17. Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS et al. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American journal of clinical dermatology. 2024;25(3):485-496. doi:10.1007/s40257-024-00853-4 Source
  18. Asilian A, Mohammadian P, Hosseini SM, Heidaripour F, Yekta A, Nateghi MR. Comparison of the effect of topical triamcinolone 0.1% cream with sulfur 2.0% cream in the treatment of patients with hand eczema: A randomized controlled trial. Journal of cosmetic dermatology. 2024;23(5):1753-1757. doi:10.1111/jocd.16208 Source
  19. Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. The New England journal of medicine. 2023;388(12):1080-1091. doi:10.1056/NEJMoa2206714 Source
  20. Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. The New England journal of medicine. 2023;389(17):1579-1589. doi:10.1056/NEJMoa2301333 Source

CarePlanRx™

Clarity that travels with you.

CarePlanRx™ resources are designed to complement provider instructions, improve follow-through, and help people ask better questions at the right time.